
Supplementary Figure S1. Optimal TMB cutoff value by ORR



An ROC analysis was performed to evaluate the therapeutic best effects of pembrolizumab for attaining a CR or PR. The area under the curve (AUC) from the ROC analysis was 0.621 (95% confidence interval: 0.50 - 0.739), and the optimal cut-off value for TMB-high status in these pembrolizumab-treated cases of breast cancer was 14.0 mut/Mb.